Vaccines and Thimerosal
- CDC Study on "Prenatal and Infant Exposure to Thimerosal from Vaccines and Immunoglobins and Risk of Autism" (2010)
- CDC Study on "Infant and Environmental Exposures to Thimerosal and Neuropsychological Outcomes at Ages 7 to 10 Years" (2007)
- CDC: Immunization Safety and Autism - Thimerosal and Autism Research chart [PDF - 30 KB]
- Frequently Asked Questions about Thimerosal
- Timeline: Thimerosal in Vaccines (1999-2008)
- Measles, Mumps, and Rubella (MMR) Vaccine
Related ResearchCenters for Disease Control and Prevention. Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR 1999:48(43);996-998.
McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children < 2 years of age: Examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine. Vaccine 2008;26(3):427–429.
Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F; Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. New England Journal of Medicine 2007;357(13):1281–1292.